Quarterly report pursuant to Section 13 or 15(d)

Nature of Operations and Business Activities (Details)

v3.23.1
Nature of Operations and Business Activities (Details)
3 Months Ended
Feb. 16, 2023
USD ($)
$ / shares
shares
Nov. 10, 2022
USD ($)
Mar. 31, 2023
USD ($)
$ / shares
Mar. 31, 2022
USD ($)
Jan. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Nature Of Operations And Business Activities [Line Items]            
Working capital deficit     $ 4,916,609      
Accumulated deficit     71,905,285     $ 66,737,765
Cash and cash equivalents     2,668,697 $ 6,006,869    
Operating loss     3,100,158 2,888,021    
Net loss     5,167,520 $ 3,043,399    
Estimate for legal contingency     6,205,310   $ 6,205,310 $ 6,205,310
Number of EHT warrants outstanding (in shares) | shares 0          
MTA Warrants, Credit Consideration            
Nature Of Operations And Business Activities [Line Items]            
Common stock issuance costs $ 1,597,236   $ 1,597,236      
Common Stock Warrants | MTA Warrants            
Nature Of Operations And Business Activities [Line Items]            
Exercise price (in dollars per share) | $ / shares $ 282,905   $ 282,905      
Discontinued Operations, Disposed of by Sale | Verdelite SPA            
Nature Of Operations And Business Activities [Line Items]            
Aggregate purchase price   $ 9,385,064        
Proceeds from asset sale, net of legal expenses   $ 5,532,266        
Emerald Health Therapeutics, Inc.            
Nature Of Operations And Business Activities [Line Items]            
Exchange ratio   1.95